Necrobiosis Lipoidica

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Processa Pharmaceuticals
2 programs
2
PCS499Phase 21 trial
PCS499Phase 21 trial
Active Trials
NCT03698864Completed12Est. Feb 2020
NCT04800562Terminated4Est. Apr 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Processa PharmaceuticalsPCS499
Processa PharmaceuticalsPCS499

Clinical Trials (2)

Total enrollment: 16 patients across 2 trials

NCT04800562Processa PharmaceuticalsPCS499

A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Start: Apr 2021Est. completion: Apr 20234 patients
Phase 2Terminated
NCT03698864Processa PharmaceuticalsPCS499

A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

Start: Nov 2018Est. completion: Feb 202012 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space